Key Points
- Teva EVP Eliyahu Sharon Kalif sold 345,810 shares on Feb. 26 at an average price of $33.64 for about $11.63 million, cutting his stake by 85.75% and leaving him with 57,478 shares (~$1.93 million).
- Strong quarterly results and guidance: Teva reported EPS of $0.96 vs. $0.65 expected and revenue of $4.71B vs. $4.36B, and set FY2026 guidance of 2.570–2.770 EPS.
- Analyst sentiment improving: Multiple firms have raised price targets (Goldman Sachs to $45, Piper Sandler to $40) and the MarketBeat average target is $37.56 with a "Moderate Buy" consensus.
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the completion of the sale, the executive vice president owned 57,478 shares of the company's stock, valued at $1,933,559.92. The trade was a 85.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
Teva Pharmaceutical Industries Price Performance
Shares of TEVA stock opened at $33.77 on Tuesday. Teva Pharmaceutical Industries Ltd. has a 1 year low of $12.47 and a 1 year high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The firm's 50 day moving average is $32.99 and its 200-day moving average is $25.92. The firm has a market capitalization of $38.83 billion, a price-to-earnings ratio of 28.14, a PEG ratio of 11.33 and a beta of 0.72.
Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The business's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
TEVA has been the topic of a number of research reports. The Goldman Sachs Group upped their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research report on Monday, February 9th. Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an "overweight" rating in a research note on Monday, December 22nd. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Saturday, January 31st. Scotiabank increased their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a research note on Thursday, January 29th. Finally, Bank of America raised their price target on Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $37.56.
Get Our Latest Research Report on Teva Pharmaceutical Industries
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Norges Bank bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $1,098,060,000. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Teva Pharmaceutical Industries by 51.4% in the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 33,390,327 shares of the company's stock worth $559,622,000 after purchasing an additional 11,334,780 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its position in Teva Pharmaceutical Industries by 31.9% in the second quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company's stock valued at $645,148,000 after purchasing an additional 9,303,978 shares during the last quarter. Soundwatch Capital LLC bought a new position in Teva Pharmaceutical Industries in the second quarter valued at about $143,533,000. Finally, Wellington Management Group LLP boosted its stake in shares of Teva Pharmaceutical Industries by 39,228.4% during the third quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company's stock valued at $139,296,000 after purchasing an additional 6,878,304 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.
About Teva Pharmaceutical Industries
(
Get Free Report)
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
